Heart Failure
This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).
Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA.
Feature | Heart Failure | February 21, 2020 | Dave Fornell, Editor
There are several new tools being added to the clinical armamentarium in the fight against heart failure (HF). These...
Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced hemodynamic support methods, as shown here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. Photo by Dave Fornell.
Feature | Heart Failure | February 20, 2020 | Dave Fornell, Editor
There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this...
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption...
Videos | Heart Failure | February 10, 2020
Interview with James Udelson, M.D., chief of the division of cardiology at Tufts Medical Center, Boston. The hospital...
The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack.
News | January 22, 2020
January 22, 2020 – BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a...
This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.
News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a...
News | Ventricular Assist Devices (VAD) | January 07, 2020
January 7, 2020 — Abbott announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical...
News | January 07, 2020
January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA)...
News | Cardiac Diagnostics | December 19, 2019
December 19, 2019 — The U.S. Food and Drug Administration (FDA) has granted breakthrough status for a novel ECG-based...
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling,...
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System for delivering CCM therapy, announced the...
News | AHA | November 21, 2019
Eko and Mayo Clinic Prove Heart Failure is Detectable at Point of Care Using ECG-Enabled Stethoscope
November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying...
News | Heart Failure | November 21, 2019
November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of...
John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session. Photo by AHA/Phil McCarten
Blog | Heart Failure | November 21, 2019
It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including...
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of...
